To enact section 3701.265 of the Revised Code to create the Triple Negative Breast Cancer Commission.

Section 1. That section 3701.265 of the Revised Code be enacted to read as follows:

Sec. 3701.265.  (A) As used in this section, "triple negative breast cancer" means the subtype of breast cancer characterized by cells that lack receptors for the hormones estrogen and progesterone and the protein receptor known as the human epidermal growth factor receptor2, or HER2, and therefore cannot be treated with breast cancer drugs that target these receptors, including such drugs as tamoxifen and trastuzumab.

(B) There is hereby created the triple negative breast cancer commission for the following purposes:

(1) To gain a better understanding of why triple negative breast cancer is more common among women who are African-American, Hispanic, under forty years of age, and living in lower socioeconomic conditions;

(2) To promote the study of triple negative breast cancer by scientists and other researchers, physicians, and educators;

(3) To increase public awareness of triple negative breast cancer.

(C) The director of health shall appoint the members of the commission. The membership shall include individuals who are familiar with triple negative breast cancer, including health care professionals and individuals who have been personally affected by the disease.

In making the appointments, the director shall specify the length of each member's term. Members may be reappointed.

Members shall receive no compensation, except to the extent that serving as a member is part of the individual's regular duties of employment.

(D) The commission shall annually select from among its members a chairperson. The commission shall meet at the call of the chairperson, but not less than twice each year. A majority of the members of the commission constitutes a quorum for the transaction of business.

(E) Sections 101.82 to 101.87 of the Revised Code do not apply to the commission.